AmideBio

Executive Summary

AmideBio is a Boulder-based biotechnology company combining proprietary in-silico design with advanced peptide synthesis to develop novel peptide therapeutics for metabolic diseases. Founded in 2013, the company operates at the preclinical stage, with a lead program targeting GLP-1 or related pathways for obesity and diabetes. AmideBio's platform leverages computational modeling to optimize peptide stability, potency, and selectivity, addressing key limitations of existing peptide drugs. The company's integrated approach also includes a service business providing custom high-purity peptides to research organizations, generating revenue and validating its manufacturing capabilities. AmideBio's dual strategy mitigates risk: the service segment provides near-term cash flow, while the therapeutic pipeline offers long-term upside. The lead candidate is advancing toward IND-enabling studies, with potential for out-licensing to larger pharmaceutical partners. Financially, the company has not disclosed total funding, but its moderate burn rate and service revenue suggest a lean operation. Key upcoming milestones include completion of GLP toxicology studies and initial first-in-human trial designs. If successful, AmideBio could capture a share of the multi-billion-dollar metabolic disease market, though competition from established GLP-1 players is significant. The company's differentiated peptide engineering approach may provide advantages in dosing frequency and tolerability.

Upcoming Catalysts (preview)

• Q3 2026Completion of IND-Enabling GLP Tox Studies70% success
• Q4 2026Pharmaceutical Partnership for Lead Peptide Candidate60% success
• Q2 2026Award of NIH SBIR Grant for Metabolic Program65% success